Femara lowers estrogen levels in postmenopausal women, which may slow the growth of certain types of breast tumors that need estrogen to grow in the body.
The launch of the drug follows the settlement and licensing agreement with Novartis.
Femara lowers estrogen levels in postmenopausal women, which may slow the growth of certain types of breast tumors that need estrogen to grow in the body.
The launch of the drug follows the settlement and licensing agreement with Novartis.